These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18952898)

  • 1. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.
    Kim WI; Matise I; Diers MD; Largaespada DA
    Blood; 2009 Jan; 113(5):1086-96. PubMed ID: 18952898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
    Sachs Z; LaRue RS; Nguyen HT; Sachs K; Noble KE; Mohd Hassan NA; Diaz-Flores E; Rathe SK; Sarver AL; Bendall SC; Ha NA; Diers MD; Nolan GP; Shannon KM; Largaespada DA
    Blood; 2014 Nov; 124(22):3274-83. PubMed ID: 25316678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
    Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
    Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
    Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J
    Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heritable genetic background alters survival and phenotype of Mll-AF9-induced leukemias.
    Young K; Loberg MA; Eudy E; Schwartz LS; Mujica KD; Trowbridge JJ
    Exp Hematol; 2020 Sep; 89():61-67.e3. PubMed ID: 32768438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rac1 signaling protects monocytic AML cells expressing the MLL-AF9 oncogene from caspase-mediated apoptotic death.
    Hinterleitner C; Huelsenbeck J; Henninger C; Wartlick F; Schorr A; Kaina B; Fritz G
    Apoptosis; 2013 Aug; 18(8):963-79. PubMed ID: 23624644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.
    Xue L; Pulikkan JA; Valk PJ; Castilla LH
    Blood; 2014 Jul; 124(3):426-36. PubMed ID: 24894773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
    Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
    Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
    Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
    Chen Y; Ernst P
    Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.
    Ghisi M; Kats L; Masson F; Li J; Kratina T; Vidacs E; Gilan O; Doyle MA; Newbold A; Bolden JE; Fairfax KA; de Graaf CA; Firth M; Zuber J; Dickins RA; Corcoran LM; Dawson MA; Belz GT; Johnstone RW
    Cancer Cell; 2016 Jul; 30(1):59-74. PubMed ID: 27374225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia.
    Manara E; Baron E; Tregnago C; Aveic S; Bisio V; Bresolin S; Masetti R; Locatelli F; Basso G; Pigazzi M
    Blood; 2014 Jul; 124(2):263-72. PubMed ID: 24695851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
    Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
    Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment?
    Muntean AG; Hess JL
    Cancer Cell; 2008 Jun; 13(6):465-7. PubMed ID: 18538728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine.
    Chen X; Clark J; Wunderlich M; Fan C; Davis A; Chen S; Guan JL; Mulloy JC; Kumar A; Zheng Y
    Autophagy; 2017 May; 13(5):955-966. PubMed ID: 28282266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIRT2 regulates proliferation and chemotherapy response of MLL-ENL-driven acute myeloid leukemia.
    Hao C; Shao X; Song J; Peng M; Lao Y; Mack R; Zhang L; Wei W; Liu N; Wang T; Wu Y; Feng L; Yin L; Wang S; Sun X; Chen S; Zhang J; Li B
    Biochem Biophys Res Commun; 2022 Mar; 596():36-42. PubMed ID: 35108652
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Liu J; Guo B; Chen Z; Wang N; Iacovino M; Cheng J; Roden C; Pan W; Khan S; Chen S; Kyba M; Fan R; Guo S; Lu J
    Blood; 2017 Mar; 129(11):1491-1502. PubMed ID: 28053194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia.
    Wang H; Bei L; Shah CA; Huang W; Platanias LC; Eklund EA
    Oncogene; 2018 May; 37(19):2532-2544. PubMed ID: 29459712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.
    Wei J; Wunderlich M; Fox C; Alvarez S; Cigudosa JC; Wilhelm JS; Zheng Y; Cancelas JA; Gu Y; Jansen M; Dimartino JF; Mulloy JC
    Cancer Cell; 2008 Jun; 13(6):483-95. PubMed ID: 18538732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-terminal BRE inhibits cellular proliferation and increases sensitivity to chemotherapeutic drugs of MLL-AF9 acute myeloid leukemia cells.
    Pun CC; Lee KK; Chui YL
    Leuk Lymphoma; 2019 Dec; 60(12):3011-3019. PubMed ID: 31111759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.